Yuling Luo rang the Nasdaq closing bell Friday having taken his first company public in a massively oversubscribed round. The Alamar Biosciences CEO’s IPO was one of two back-to-back blockbuster biotech offerings this week, a clear signal that investors are willing to open their wallets for life sciences companies again—under the right conditions.
On Thursday, Kailera Therapeutics, an obesity drug developer, raised $625 million in what is believed to be the largest biotech IPO in Nasdaq history. The IPO priced 39.1 million shares at $16 (the top of its range). The company had initially set out to raise just $500 million. One day post-IPO, Kailera was already up 63 percent.
On Friday, Alamar Biosciences, a precision proteomics (the study of proteins rather than genes) firm, priced its own upsized offering at $17 per share (the top of its range) raising $191.3 million after demand exceeded available shares by 11 times, Luo told Fortune. Much like Kailera, Alamar shares soared, up 33% on the first day of trading.
For Alamar in particular, the listing carries symbolic weight. The life sciences tools and diagnostics sector has been effectively shut out of the public markets since 2021, when
MedTech IPO activity peaked at 61 companies going public. A brutal stretch followed: Only two U.S. MedTech companies went public in each of 2022 and 2023, according to FLG Partners data. The tools sub-sector, where Alamar operates, has remained dormant.
Luo attributed the IPO drought—and Alamar’s ability to end it—to a long-awaited technological breakthrough in early disease detection of cancer and Alzheimer’s. The company’s platform can detect disease signals in blood that are too faint for existing tools to pick up. He compared the product’s detection capabilities as being able to read an eye exam chart from 37 miles away.
“I think that’s why it’s been five years, because investors now see the great potential in proteomics. Everyone recognizes we finally have technology that could unlock it,” Luo told Fortune. He sees proteomics as the next frontier after genomics: where gene-sequencing gives doctors a static snapshot of a patient’s DNA, protein analysis offers a real-time window into how disease is actually unfolding inside the body.
Alamar operates in a market valued at over $36 billion in 2025 and expected to reach $65.8 billion by 2030. The company tripled revenue from $25 million to $74 million in two years despite what Luo called “one of the most difficult market environments” for the tools industry.
Kailera is staking its claim in an even hotter opportunity and space: the global obesity GLP-1 market, currently worth roughly $10 billion and projected to reach $66.57 billion by 2035, growing at a 23% CAGR. The company is going head-to-head with Novo Nordisk and Eli Lilly, developing injectable and oral GLP-1 agonists.
The back-to-back pricings arrive at a complicated moment for biotech more broadly. Private bio/pharma funding in 2025 totaled roughly $40 billion across 1,045 deals, essentially flat with 2024. Meanwhile, the overall venture market has been dominated by AI. About 80% of global venture capital in Q1 2026 flowed to AI companies, with four mega-deals (OpenAI, Anthropic, xAI, and Waymo) accounting for more than $188 billion of the record $300 billion quarter. That dynamic has squeezed attention and capital for non-AI sectors, even as PitchBook data showed biotech deal activity climbing back to its highest level since late 2022 in Q4 2025.
The broader IPO market has struggled to find its footing too: early 2026 listings were “much slower than was expected,” Crunchbase research lead Gené Teare previously told Fortune, with attention consumed by AI giants like OpenAI, SpaceX, and Anthropic that have yet to list. When they do, Teare said, it could “create a lot of energy in the markets for other companies to also go out”—or simply crowd everyone else out.
Analysts had projected 30 to 35 biotech IPOs for 2026. This week’s deals suggest the window may finally be cracking open—at least for companies with late-stage data and differentiated science to show investors.
Yuling Luo, CEO of Alamar Biosciences, made headlines by ringing the Nasdaq closing bell after successfully taking his company public in a significant IPO, signaling renewed investor interest in biotech. Alamar’s IPO followed closely on the heels of Kailera Therapeutics’ record-setting offering, further indicating that investors are beginning to engage with life sciences companies under favorable conditions.
Kailera Therapeutics, which focuses on developing obesity drugs, raised an impressive $625 million, marking what is likely the largest biotech IPO in Nasdaq history. The company initially aimed for $500 million but ended up pricing its shares at $16, the top of its range, for 39.1 million shares. Following the IPO, Kailera’s stock surged by 63% within just one day, showcasing strong investor demand.
Alamar Biosciences also capitalized on this momentum, pricing its own IPO at $17 per share, raising $191.3 million after 11 times the demand for available shares, according to Luo. Like Kailera, Alamar’s shares experienced a significant rise, increasing by 33% on their first trading day.
The successful public listings are particularly momentous for Alamar, as the life sciences tools and diagnostics sector had been largely inactive in public markets since 2021, when MedTech IPOs peaked. In stark contrast, only two U.S. MedTech companies went public in both 2022 and 2023. Alamar’s entry into the public market marks a potential turning point for this sub-sector, which has been dormant for several years.
Luo attributes the stagnation in IPO activity and Alamar’s successful debut to a significant technological advancement in early disease detection for conditions like cancer and Alzheimer’s. Alamar’s innovative platform can detect subtle disease signals in blood that existing technology typically misses. Luo likened the detection capability to being able to read an eye exam chart from an extraordinary distance of 37 miles. He believes that the advancements in proteomics—where protein analysis can provide real-time insights into disease progression—are finally being recognized by investors, positioning proteomics as the next frontier after genomics.
Alamar operates in a rapidly growing market, which was valued at over $36 billion in 2025 and is projected to reach $65.8 billion by 2030. The company has managed to triple its revenue in just two years, increasing from $25 million to $74 million, despite facing « one of the most difficult market environments » for the tools industry.
In contrast, Kailera is targeting the lucrative global obesity GLP-1 market, which is currently estimated at $10 billion and is expected to explode to $66.57 billion by 2035, experiencing a compound annual growth rate (CAGR) of 23%. The company is positioning itself against major competitors like Novo Nordisk and Eli Lilly, focusing on both injectable and oral GLP-1 agonists.
The timing of these IPOs is complex, as the broader biotech landscape is navigating a challenging environment. In 2025, private funding for bio/pharma reached around $40 billion across 1,045 deals, which remained stable compared to 2024. However, the venture capital landscape has been heavily dominated by AI, with around 80% of global venture capital in Q1 2026 directed toward AI companies. This shift has diverted attention and capital away from non-AI sectors, although biotech deal activity showed signs of recovery, reaching its highest level since late 2022 in the last quarter of 2025.
The overall IPO market has also struggled to regain traction, with early 2026 listings falling short of expectations. The focus has been largely on AI giants such as OpenAI and SpaceX, which have not yet gone public. Analysts predict that when these companies eventually list, it could energize the market for other firms or potentially overshadow them.
Looking ahead, analysts had estimated that there would be 30 to 35 biotech IPOs in 2026. The recent successful listings of Kailera and Alamar suggest that the IPO window may be beginning to open, at least for companies that can present compelling late-stage data and innovative science to attract investor interest.
In summary, the successful IPOs of Alamar Biosciences and Kailera Therapeutics represent a significant moment for the biotech sector, signaling a possible resurgence in investor interest and activity in life sciences, particularly for companies demonstrating groundbreaking technologies and robust market potential.
